Information de reference pour ce titreAccession Number: | 01823275-201706000-00025.
|
Author: | Zhao, Feng 1, *; Wang, Yijuan 1, *; Liu, Lin 2; Bian, Meiling 3
|
Institution: | (1) Department of Blood Transfusion Medicine, Linzi District People's Hospital, Binzhou Medical University, Zibo, Shandong 255400, P.R. China (2) Medical Intensive Care Unit, PKU Care Luzhong Hospital, Zibo, Shandong 255400, P.R. China (3) Department of Internal Medicine, Linzi District People's Hospital, Binzhou Medical University, Zibo, Shandong 255400, P.R. China
|
Title: | |
Source: | Molecular and Clinical Oncology. 6(6):925-930, June 2017.
|
Abstract: | The present study aimed to evaluate the effectiveness of erythropoietin (EPO) for improving cancer-associated malignant anemia. A search was performed for randomized clinical trials, conducted according to the Cochrane manual, using electronic databases including PubMed, EMBASE, the Cochrane Library and ClinicalTrails.gov up to 15 August 2015. A total of 6 eligible studies from 5 articles enrolling a total of 453 patients were entered into the current meta-analysis. Upon EPO treatment, there were significant differences in the change in hemoglobin (HB) levels compared with the placebo at short-term follow-up [mean difference (MD)=0.66; 95% confidence interval (CI), 0.14-1.18; I2=Not applicable; P=0.01) and long-term follow-up (MD=0.10; 95% CI, 0.02-0.18; I2=Not applicable; P=0.01) under the random effects model. For changes in hematocrit (HCT) compared with the placebo, the results revealed there were significant differences at short-term follow-up (MD=2.47; 95% CI, 0.75-4.19; I2=Not applicable; P=0.005) and long-term follow-up (MD=7.60; 95% CI, 6.15-9.05; I2=Not applicable; P<0.00001) under the random effects model. Compared with the placebo in short-term follow-up under the fixed effects model with homogeneity, the result was a significant difference for the transfusion ratio [relative risk (RR)=0.81; 95% CI, 0.67- 0.97; I2=34%; P=0.02) and the transfusion requirements (MD=-0.45; 95% CI, -0.92, 0.03; I2=6%; P=0.07). Funnel plots did not detect any publication bias. These results suggest that EPO was beneficial to alleviate cancer-associated anemia and improve survival outcomes for patients with cancer.
(C) Spandidos Publications 2017.
|
Author Keywords: | erythropoietin; cancer-associated malignant anemia; hemoglobin; meta-analysis.
|
References: | 1. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev 26: 303-311, 2000; 10.1053/ctrv.2000.0181.
2. Henry DH. Supplemental Iron: A key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 3: 275-278, 1998.
3. Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol 58: 251-216, 1997; 10.1111/j.1600-0609.1997.tb01663.x.
4. Pronzato P. Cancer-related anaemia management in the 21st century. Cancer Treat Rev 32: (Suppl 2): S1-S3, 2006; 10.1016/j.ctrv.2006.04.008.
5. Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, et al: Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr 127: 907-919, 2015; 10.1007/s00508-015-0893-5.
6. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 19: 19-30, 2001; 10.1002/hon.663.
7. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem. Semin Hematol 34: (3 Suppl 2): S20-S26, 1997.
8. Brandberg Y. Assessing the impact of cancer-related anaemia on quality of life and the role of rHuEPO. Med Oncol 17: Suppl 1S23-S31, 2000.
9. Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W. Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 33: 59-62, 1999; 10.1016/S0272-6386(99)70258-1.
10. Leng HM, Albrecht CF, Kidson SH, Folb PI. Erythropoietin production in anemia associated with experimental cancer. Exp Hematol 27: 806-810, 1999; 10.1016/S0301-472X(99)00016-8.
11. Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG, Swaak AJ. Regulation of iron metabolism in the acute-phase response: Interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 28: 520-527, 1998; 10.1046/j.1365-2362.1998.00323.x.
12. Chung IJ, Dai C, Krantz SB. Stem cell factor increases the expression of FLIP that inhibits IFNgamma -induced apoptosis in human erythroid progenitor cells. Blood 101: 1324-1328, 2003; 10.1182/blood-2002-06-1720.
13. Rodriguez S, anchez CA. Recommendation of the scientific societies on the treatment of anaemia in cancer patients. Clin Transl Oncol 9: 582-589, 2007; 10.1007/s12094-007-0107-3.
14. Garcia JM Jurado, Sanchez E Torres, Hidalgo D Olmos, Alba Conejo E. Erythropoietin pharmacology. Clin Transl Oncol 9: 715-722, 2007; 10.1007/s12094-007-0128-y.
15. Ahlqvist-Rastad J, Albertsson M, Bergh J, Birgegard G, Johansson P, Jonsson B, Kjellen E, Pahlman S, Zackrisson B, Osterborg A. Erythropoietin therapy and cancer related anaemia: Updated Swedish recommendations. Med Oncol 24: 267-272, 2007; 10.1007/s12032-007-0037-5.
16. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 21: 1575-1600, 2002; 10.1002/sim.1188.
17. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011; www.cochrane-handbook.org, Accessed October, 1, 2011.
18. Walter SD, Yao X. Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews. J Clin Epidemiol 60: 849-852, 2007; 10.1016/j.jclinepi.2006.11.003.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558, 2002; 10.1002/sim.1186.
20. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003; 10.1016/S0140-6736(03)14567-9.
21. Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1: 247-262, 2000; 10.1093/biostatistics/1.3.247.
22. Kettelhack C, Hones C, Messinger D, Schlag PM. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 85: 63-67, 1998; 10.1046/j.1365-2168.1998.00564.x.
23. Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: A prospective, randomized, placebo-controlled study. Laryngoscope 112: 1221-1229, 2002; 10.1097/00005537-200207000-00015.
24. Kosmadakis N, Messaris E, Maris A, Katsaragakis S, Leandros E, Konstadoulakis MM, Androulakis G. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: Prospective randomized double-blind study. Ann Surg 237: 417-421, 2003; 10.1097/00000658-200303000-00017.
25. Christodoulakis M, Tsiftsis DD. Hellenic Surgical Oncology Perioperative EPO Study Group: Preoperative epoetin alfa in colorectal surgery: A randomized, controlled study. Ann Surg Oncol 12: 718-725, 2005; 10.1245/ASO.2005.06.031.
26. Mystakidou K, Kalaidopoulou O, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Vlahos L. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Res 25: 3495-3500, 2005.
27. Lacson E, Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41: 111-124, 2003; 10.1053/ajkd.2003.50030.
28. Rainville N, Jachimowicz E, Wojchowski DM. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis. Expert Opin Ther Targets 20: 287-301, 2016; 10.1517/14728222.2016.1090975.
29. Singh PK, Devasahayam M, Devi S. Expression of GPI anchored human recombinant erythropoietin in CHO cells is devoid ofglycosylation heterogeneity. Indian J Exp Biol 53: 195-201, 2015.
30. Aapro M. Emerging topics in anaemia and cancer. Ann Oncol 23: (Suppl 10): x289-x293, 2012; 10.1093/annonc/mds345.
31. Rice L, Alfrey CP. The negative regulation of red cell mass by neocytolysis: Physiologic and pathophysiologic manifestations. Cell Physiol Biochem 15: 245-250, 2005; 10.1159/000087234.
32. Means RT, Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647, 1992.
33. Borstlap WA, Buskens CJ, Tytgat KM, Tuynman JB, Consten EC, Tolboom RC, Heuff G, van Geloven AA, van Wagensveld BA, Wientjes CA, et al: Erratum to: Multicentre randomized controlled trial comparing ferric (III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients. BMC Surg 15: 110, 2015; 10.1186/s12893-015-0090-5.
34. Lai-Tiong F, Brami C, Dubroeucq O, Scotte F, Cure H, Jovenin N. Management of anemia and iron deficiency in a cancer center in France. Support Care Cancer 24: 1091-1096, 2016; 10.1007/s00520-015-2877-4.
35. Braga M, Gianotti L, Vignali A, Gentilini O, Servida P, Bordignon C, Di Carlo V. Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg 82: 1637-1640, 1995; 10.1002/bjs.1800821216.
36. Jackson D, White IR, Mason D, Sutton S. A general method for handling missing binary outcome data in randomized controlled trials. Addiction 109: 1986-1993, 2014; 10.1111/add.12721.
|
Language: | English.
|
Document Type: | Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 2049-9450
|
DOI Number: | https://dx.doi.org/10.3892/mco.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|